Macquarie Group’s Cogent Biosciences COGT Stock Holding History

Macquarie Group’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Buy	+5,500	New	+$192K	﹤0.01%	780
2025 Q4	–	Sell	-398,830	Closed	-$5.73M	–	994
2025 Q3	$5.73M	Buy	398,830 +168,830	+73%	+$2M	0.01%	930
2025 Q2	$1.65M	Hold	230,000	–	–	﹤0.01%	1278
2025 Q1	$1.38M	Hold	230,000	–	–	﹤0.01%	1329
2024 Q4	$1.79M	Hold	230,000	–	–	﹤0.01%	1231
2024 Q3	$2.48M	Hold	230,000	–	–	﹤0.01%	1166
2024 Q2	$1.94M	Hold	230,000	–	–	﹤0.01%	1232
2024 Q1	$1.55M	Hold	230,000	–	–	﹤0.01%	1293
2023 Q4	$1.35M	Hold	230,000	–	–	﹤0.01%	1315
2023 Q3	$2.24M	Hold	230,000	–	–	﹤0.01%	1133
2023 Q2	$2.72M	Hold	230,000	–	–	﹤0.01%	1084
2023 Q1	$2.48M	Hold	230,000	–	–	﹤0.01%	1102
2022 Q4	$2.66M	Hold	230,000	–	–	﹤0.01%	1124
2022 Q3	$3.43M	Hold	230,000	–	–	﹤0.01%	1083
2022 Q2	$2.08M	Buy	+230,000	New	+$1.57M	﹤0.01%	1286

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Macquarie Group's COGT Position: Q2 2026 in Review

Macquarie Group opened a new position in Cogent Biosciences (COGT) in Q2 2026: 5,500 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #780 among its holdings. This is a return to the name: Macquarie Group previously reported a position in COGT as recently as Q3 2025.

Macquarie Group first reported a position in COGT in Q2 2022 and has held it in 15 quarters since. The position peaked at $5.73M in Q3 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Macquarie Group held 5,500 shares of Cogent Biosciences worth $213K as of Q2 2026.
Cogent Biosciences was a new Macquarie Group position in Q2 2026.
Cogent Biosciences made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #780 holding.
Macquarie Group first reported a position in Cogent Biosciences in Q2 2022 and has held it in 15 quarters since.
Macquarie Group's Cogent Biosciences position peaked at $5.73M in Q3 2025.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.